Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL

QJM: An International Journal of Medicine

Volumn 101, Issue 9, 2008, Pages 737-740

  Klepfish, Abraham ^a   Rachmilewitz, E A ^a   Kotsianidis, I ^b   Patchenko, P ^a   Schattner, Ami ^c,d  

^a Wolfson Medical Centre Holon   (Israel)

^b DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FRESH FROZEN PLASMA; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GREECE; HUMAN; ISRAEL; LYMPHADENITIS; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLASMA TRANSFUSION; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 51049121811     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn085     Document Type: Article

References (12)

1. Yee KW, O'brien SM. Chronic lymphocytic leukemia: Diagnosis and treatment. Mayo Clin Proc 2006; 81:1105-29.
2. Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR. Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. Rituximab in lymphoma: A systematic review and concensus practice guideline from Cancer Care Ontario. Cancer Treat Rev 2007; 33:161-76.
3. Byrd JC, Murphy T, Howards RS, Lucas MS, Goodrich A, Park K, et al Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153-64.
4. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al Rituximab therapy of patients with chronic lymphocytic leukemia. Blood 2001; 98:1326-31.
5. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Babui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 2001; 98:3383-9.
6. Varga L, Czink E, Miszlai Z, Paloczi K, Banyai A, Szegedi G, et al Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin Exp Immunol 1995; 99:112-6.
7. Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphocytic leukaemia patients and in their healthy relatives. Leukaemia 1996; 10:1509-13.
8. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30(1 Suppl. 2) 3-8.
9. Klepfish A, Schattner A, Ghoti H, Rachmilewitz EA. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol 2007; 8:361-2.
10. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26:3629-36.
11. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12:4027-35.
12. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172:3280-8.